Relationship between thymidylate synthase (TYMS) gene polymorphism and TYMS protein levels in patients with high-risk breast cancer

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4373-4379

  Fujishima, Makoto ^a   Inui, Hiroki ^a   Hashimoto, Yukihiko ^a   Azumi, Tatsuya ^a   Yamamoto, Nao ^a   Kato, Hiroaki ^a   Hojo, Toshiya ^a   Yamato, Munehisa ^b   Matsunami, Nobuki ^c   Shiozaki, Hitoshi ^a   Watatani, Masahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yamato Clinic   (Japan)

^c OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Breast cancer; Polymorphism; Protein level; Thymidylate synthase

Indexed keywords

FLUOROURACIL; THYMIDYLATE SYNTHASE;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; BREAST NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROURACIL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; THYMIDYLATE SYNTHASE;

EID: 78650247365     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
2. Adlard JW, Richman SD, Seymour MT and Quirke P: Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3: 75-82, 2002.
3. Etienne MC, Chazal M, Laurent-Puig P, Magné N, Rosty C, Formento JL, Francoual M, Formento P, Renée N, Chamorey E, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D and Milano G: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20: 2832-2843, 2002.
4. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A and Aherne GW: Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75: 903-909, 1997.
5. Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20: 1721-1728, 2002.
6. Gosens MJ, Moerland E, Lemmens VP, Rutten HT, Tan-Go I and van den Brule AJ: Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int J Cancer 123: 1941-1949, 2008.
7. Horie N, Aiba H, Oguro K, Hojo H and Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20: 191-197, 1995.
8. Kawakami K, Omura K, Kanehira E and Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19: 3249-3252, 1999.
9. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G and Danenberg PV: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7: 4096-4101, 2001.
10. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM and Potter JD: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9: 1381-1385, 2000.
11. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ and Ladner RD: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14: 319-327, 2004.
12. Pullmann R Jr, Abdelmohsen K, Lal A, Martindale JL, Ladner RD and Gorospe M: Differential stability of thymidylate synthase 3′-untranslated region polymorphic variants regulated by AUF1. J Biol Chem 281: 23456-63, 2006.
13. Ulrich CM, Bigler J, Bostick R, Fosdick L and Potter JD: Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res 62: 3361-3364, 2002.
14. Kurebayashi J, Yamamoto Y, Udagawa K, Okubo S, Fukushima M and Sonoo H: Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues. Oncol Rep 11: 973-979, 2004.
15. Morganti M, Ciantelli M, Giglioni B, Putignano AL, Nobili S, Papi L, Landini I, Napoli C, Valanzano R, Cianchi F, Boddi V, Tonelli F, Cortesini C, Mazzei T, Genuardi M and Mini E: Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41: 2176-2183, 2005.
16. Prall F, Ostwald C, Schiffmann L and Barten M: Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? Oncol Rep 18: 203-209, 2007.
17. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S and Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1: 65-70, 2001.
18. Yu KH, Wang WX, Ding YM, Li H and Wang ZS: Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer. World J Gastroenterol 14: 617-621, 2008.
19. Graziano F, Ruzzo A, Loupakis F, Santini D, Catalano V, Canestrari E, Maltese P, Bisonni R, Fornaro L, Baldi G, Masi G, Falcone A, Tonini G, Giordani P, Alessandroni P, Giustini L, Vincenzi B and Magnani M: Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. Br J Cancer 99: 716-721, 2008.
20. Chu J abd Dolnick BJ: Natural antisense (rTSalpha) RNA induces site-specific cleavage of thymidylate synthase mRNA. Biochim Biophys Acta 1587: 183-193, 2002.
21. Moreira LR, Almeida Schenka A, Latuff Filho P, Nascimento H, Passos Lima CS, Silva Trevisan MA and Vassallo J: Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma. Int J Surg Pathol 17: 181-186, 2009.
22. Kuramochi H, Tanaka K, Oh D, Lehman BJ, Dunst CM, Yang DY, De Meester SR, Hagen JA, Danenberg KD, De Meester TR and Danenberg PV: Thymidylate synthase polymorphisms and mRNA expression are independent chemotherapy predictive markers in esophageal adenocarcinoma patients. Int J Oncol 32: 201-208, 2008.
23. Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K and Feng JF: Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet 51: 155-160, 2006.
24. Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, Pareja L, Figueras A, Molleví DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germà JR, Capellá G and Villanueva A: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24: 1603-1611, 2006.
25. Ezzeldin HH and Diasio RB: Predicting fluorouracil toxicity: can we finally do it? J Clin Oncol 26: 2080-2082, 2008.
26. Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P and Laurent-Puig P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10: 5880-5888, 2004.
27. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C and Eichelbaum M: German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26: 2131-2138, 2008.
28. Santini D, Vincenzi B, Perrone G, Rabitti C, Borzomati D, Caricato M, La Cesa A, Grilli C, Verzì A, Coppola R and Tonini G: Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. Oncology 67: 135-142, 2004.
29. Eliason JF and Megyeri A: Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets 5: 383-388, 2004.
30. Yasumatsu R, Nakashima T, Uryu H, Ayada T, Wakasaki T, Kogo R, Masuda M, Fukushima M and Komune S: Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. Chemotherapy 55: 36-41, 2009.